Suntril Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 2.20 Cr
as on 13-12-2024
- Paid Up Capital ₹ 2.20 Cr
as on 13-12-2024
- Company Age 11 Year, 24 Days
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 4.52 Cr
as on 13-12-2024
- Revenue 50.91%
(FY 2022)
- Profit 184.06%
(FY 2022)
- Ebitda 38.39%
(FY 2022)
- Net Worth 204.83%
(FY 2022)
- Total Assets 11.10%
(FY 2022)
About Suntril Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 2.20 Cr and a paid-up capital of Rs 2.20 Cr.
The company currently has active open charges totaling ₹4.52 Cr.
Pardeep Narula and Trilok Narula serve as directors at the Company.
- CIN/LLPIN
U24232CH2013PTC034849
- Company No.
034849
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
29 Nov 2013
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Chandigarh
Industry
Company Details
- LocationChandigarh, Chandigarh
- Telephone
- Email Address
- Website
- Social Media-
What products or services does Suntril Pharmaceuticals Private Limited offer?
Suntril Pharmaceuticals Private Limited offers a wide range of products and services, including Pharmaceutical Tablets, Deferasirox Tablets, Anti Infective API, Tigecycline API, Pharma Ingredients & Raw Materials, Chemical Intermediates, Triethylamine, API (Active Pharmaceutical Ingredients), Strontium Ranelate API, Common Disease Medicines.
Who are the key members and board of directors at Suntril Pharmaceuticals?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Pardeep Narula  | Managing Director | 29-Nov-2013 | Current |
Board Members(1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Trilok Narula | Additional Director | 13-Apr-2015 | Current |
Financial Performance of Suntril Pharmaceuticals.
Suntril Pharmaceuticals Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 50.91% increase. The company also saw a substantial improvement in profitability, with a 184.06% increase in profit. The company's net worth Soared by an impressive increase of 204.83%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Suntril Pharmaceuticals?
In 2022, Suntril Pharmaceuticals had a promoter holding of 80.00% and a public holding of 20.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Bank Of India Creation Date: 25 Nov 2021 | ₹3.77 M | Open |
Bank Of India Creation Date: 15 Sep 2015 | ₹4.14 Cr | Open |
How Many Employees Work at Suntril Pharmaceuticals?
Suntril Pharmaceuticals has a workforce of 18 employees as of Apr 02, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Suntril Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Suntril Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
